PPARA and primary biliary cholangitis: Some agents are not new (eg, fibrates targeting PPAR alpha), whereas others are investigational (saroglitazar, targeting PPARα/γ) or are recently approved (elafibranor targeting PPARα/γ; seladelpar targeting PPAR delta) as second-line therapy for PBC (recently reviewed225 and relevant studies226–229).